<DOC>
	<DOC>NCT00792298</DOC>
	<brief_summary>A cross-over, polysomnography study to test the safety, tolerability and effectiveness of different doses of suvorexant (MK-4305) in the treatment of patients with primary insomnia.</brief_summary>
	<brief_title>Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
	<mesh_term>Suvorexant</mesh_term>
	<criteria>Has a diagnosis of Primary Insomnia based on sleep history and the investigator's judgment Must be willing to stay overnight at a sleep laboratory Must be willing to stay in bed for at least 8 hours each night while at the sleep laboratory Regular bedtime is between 9 PM and 12 AM (midnight) Breast feeding, pregnant or planning to become pregnant during the study Within the past 6 months before starting the study you have a history of significant cardiovascular disorder such as unstable angina, congestive heart failure or acute coronary syndrome Currently participating or have participated in a study with an investigational compound or device within the last 30 days Has traveled across 3 or more time zones in the last 2 weeks or plans on traveling across 3 or more time zones at any time during the study Has done shift work within the past 2 weeks Has donated blood products within the last 8 weeks Has difficulty sleeping due to a medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>